The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
AGILE THERAPEUTICS, INC. | Common Stock | 00847L100 | 8,737 | 1,958,875 | SH | SOLE | 1,958,875 | 0 | 0 | ||
AGILE THERAPEUTICS, INC. | Common Stock | 00847L100 | 13,842 | 3,103,488 | SH | DFND | 1 | 3,103,488 | 0 | 0 | |
EAGLE PHARMACEUTICALS, INC. | Common Stock | 269796108 | 404 | 6,777 | SH | SOLE | 6,777 | 0 | 0 | ||
IMMUNE DESIGN CORP. | Common Stock | 45252L103 | 14,627 | 1,413,280 | SH | SOLE | 1,413,280 | 0 | 0 | ||
MERSANA THERAPEUTICS, INC. | Common Stock | 59045L106 | 16,524 | 955,709 | SH | DFND | 1 | 955,709 | 0 | 0 | |
UROGEN PHARMA LTD. | Common Stock | M96088105 | 45,696 | 1,449,745 | SH | SOLE | 1,449,745 | 0 | 0 |